Daraprim TPP Settlement

By providing your information, either on paper, electronically or through a website, you consent to us storing and using your information for case administration purposes only. Our site uses tracking technologies to tailor your experience and understand how you and other visitors use our site. By continuing to navigate this site you consent to use of these tracking technologies. For more information on how we use your personal data, please read our Privacy Policy.

Daraprim TPP Settlement
Home
Home
Notice
Notice
Claim Form
Claim Form
Court Documents
Court Documents
Contact Information
Contact Information

The information contained on this website is only a summary.  You may download a copy of the full Notice by clicking here.  Since this website is just a summary, you should review the Notice for additional details.


If you are a Third-Party Payor and made payments or reimbursements
for some or all of the purchase price of Daraprim from August 7, 2015,
through January 28, 2022, you may be eligible for a payment from a class action settlement.


The Settlement provides a minimum cash payment to the Settlement Class of $7 million and additional potential cash payments totaling up to $21 million for a total potential settlement amount of up to $28 million.

The lawsuit, BCBSM, Inc. v. Vyera Pharmaceuticals, et al. No. 21-cv-1884-DLC (the “Action”) is pending in the United States District Court for the Southern District of New York (the “Court”). The lawsuit claims that Defendants Vyera Pharmaceuticals, LLC and Phoenixus AG, Martin Shkreli, and Kevin Mulleady engaged in a scheme to thwart generic competition for Daraprim in violation of Sections 1 and 2 of the Sherman Act and various state antitrust, unjust enrichment, and consumer protection laws.


WHAT DO THE SETTLEMENTS PROVIDE?

The Settlement provides a minimum cash payment to the Settlement Class of $7 million and additional potential cash payments totaling up to $21 million for a total potential settlement amount of up to $28 million.

As part of the Class Contingent Payments, the Corporate Defendants will pay into the Class Settlement Fund 14% of the net proceeds they earn from monetizing a Corporate Asset other than a Priority Review Voucher, and 14% of the net proceeds they earn from monetizing a Ketamine asset, based on any transactions executed over the next five years, up to a total of $10.5 million. The Corporate Defendants will also pay the Settlement Class 14% of the net proceeds they earn from any transaction monetizing a Priority Review Voucher executed over the next 10 years, with total Class Contingent Payments to the Settlement Class capped at $21 million.  

  

WHO IS INCLUDED IN THE SETTLEMENT CLASS?

All entities that, for consumption by their members, employees, insureds, participants, or beneficiaries, and not for resale, indirectly purchased, paid, and/or provided reimbursement for some or all of the purchase price of Daraprim during the Settlement Class Period (August 7, 2015, through January 28. 2022The types of third-party payor entities that might fall within the Settlement Class include health insurance companies; union health and welfare benefit plans; self-insured employers; and entities with self-funded plans that contract with a health insurance company or other entity to serve as a third-party claims administrator to administer their prescription drug benefits.

Excluded from the Settlement Class are the following:

(a)     Natural person consumers;

(b)     Defendants and their employees, affiliates, parents, and subsidiaries, whether or not named in the Complaint;

(c)     All federal and state governmental entities except for cities, towns, municipalities, or counties with self-funded prescription drug plans;

(d)     Fully insured health plans (i.e., health plans that purchased insurance covering 100% of their reimbursement obligation to members); and

(e)     Judges assigned to this case and any members of their immediate families.



YOUR LEGAL RIGHTS AND OPTIONS

FILE A CLAIM

Third-party payors must submit a Claim Form postmarked (if mailed) or filed online by June 1, 2022 to be eligible for a payment from the Settlement.  The Claim Form, and instructions on how to submit it, are available on the Claim Form page of this website.

EXCLUDE YOURSELF

You may exclude yourself from the Settlement Class and keep your right to sue at your own expense.  If you exclude yourself, you will not receive any payment from the Settlements. A written Request for Exclusion must be received by April 18, 2022. 

OBJECT TO THE SETTLEMENT

If you do not exclude yourself, you may object to or comment on the Settlement, the proposed Plan of Allocation, and/or the request for attorneys’ fees and litigation expenses. Written objections must be received by May 23, 2022.

DO NOTHING

You are automatically part of the class action if you fit the definition of the Settlement Class.  However, if you do not file a claim by June 1, 2022, you will not receive any payment from the Settlement. 


adobe reader imageYou will need Adobe Reader to view documents on this site. You can learn more about Adobe Reader and download the latest version by clicking here.